ML-004 in Adolescents and Adults with Autism Spectrum Disorders (ASD)
Purpose
ML-004-002 is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study that will enroll approximately 150 adolescent and adult subjects with ASD. The primary objective is to evaluate the efficacy of ML-004 compared with placebo in the improvement of social communication deficits in subjects with ASD.
Condition
- Autism Spectrum Disorder
Eligibility
- Eligible Ages
- Between 12 Years and 45 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Age 12 to 45 at screening - Has a designated care/study partner who can reliably report on symptoms - Has a diagnosis of Autism Spectrum Disorder (ASD) - Has a body mass index (BMI) 18 through 34 kg/m², inclusive - Full scale IQ (or equivalent) ≥55 score, with adequate verbal fluency, as determined by the Principal Investigator. - Psychoactive medications and adjunctive therapies are stable for 4 weeks prior to screening - Must be able to swallow study medication
Exclusion Criteria
- Has Rett syndrome or Child Disintegrative Disorder - Has participated in any other study and received any other investigational medication (other than COVID-19 vaccination) or device within 60 days prior to screening - History of epilepsy without current adequate control, or any seizure in the 6 months preceding screening - History of suicidal ideation or behavior in the past 12 months, or a positive response to C-SSRS questions 4 and/or 5 - Systolic blood pressure ≥140 mmHg (if adult) or >135 mmHg (if adolescent), or diastolic blood pressure ≥90 (if adult) or >85 mmHg (if adolescent), or a clinical history of uncontrolled or severe hypertension - If female, is pregnant or lactating
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Intervention Model Description
- Multi-center, randomized, double-blind, placebo-controlled study
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Masking Description
- Double-blind
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental ML-004 (IR)/(ER) tablet |
ML-004 is a bilayer immediate-release (IR)/extended-release (ER, gastroretentive) oral tablet formulation. ML-004 is taken orally once daily and provided as a tablet in two dose strengths of 12 mg (3 mg IR/9 mg ER) and 24 mg tablet (6 mg IR/18 mg ER). Dose levels for this study are 12 mg (provided as one 12 mg tablet), 24 mg (one 24 mg tablet), 48 mg (two 24 mg tablets), and 72 mg (three 24 mg tablets). |
|
|
Placebo Comparator ML-004 Placebo |
Matched placebo oral tablets will consist of same excipients as the investigational drug but without any ML-004. Placebo taken orally once daily to match tablet number of ML-004 dose levels for 12 mg (1 tablet), 24 mg (1 tablet), 48 mg (2 tablets), and 72 mg (3 tablets). |
|
Recruiting Locations
Children's National and nearby locations
Children's National Health System - The Children's Research Institute (CRI)
Washington, District of Columbia 20010
Washington, District of Columbia 20010
Contact:
Adelaide Robb, MD
202-476-3042
Adelaide Robb, MD
202-476-3042
More Details
- NCT ID
- NCT05081245
- Status
- Recruiting
- Sponsor
- MapLight Therapeutics